{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Cediranib_Maleate",
  "nciThesaurus": {
    "casRegistry": "857036-77-2",
    "chebiId": "",
    "chemicalFormula": "C25H27FN4O3.C4H4O4",
    "definition": "The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth.",
    "fdaUniiCode": "68AYS9A614",
    "identifier": "C48379",
    "preferredName": "Cediranib Maleate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "AZD2171",
      "AZD2171 Maleate",
      "CEDIRANIB MALEATE",
      "Cediranib Maleate",
      "Quinazoline, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-",
      "Recentin",
      "cediranib maleate"
    ]
  }
}